1.
Bioorg Med Chem Lett
; 19(12): 3174-6, 2009 Jun 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19447034
RESUMO
In this study the first PDE4B selective inhibitor is described. Optimization of lead 2-arylpyrimidine derivatives afforded a series of potent PDE4B inhibitors with >100-fold selectivity over the PDE4D isozyme. With a good pharmacokinetic profile, a selected compound exhibited potent anti-inflammatory effects in vivo and showed less emesis compared with Cilomilast.